Guide

Biosimilars pipeline report: A guide for understanding the growing market 

To date, there have been 59 approvals and 41 launches in the U.S. biosimilars market. 
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

To view and read this report, please fill out the form. 

Related resources

Newsletter

HTA Quarterly Summer 2026

Article

Rare diseases and orphan drugs: Assessing the PV implications

Article

AI-assisted quality assessment in HEOR: What works, what doesn’t, and how to apply GenAI responsibly

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
abstract